Literature DB >> 7849490

Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey.

W M Galbraith1, W C Hobson, P C Giclas, P J Schechter, S Agrawal.   

Abstract

Rapid intravenous infusion of GEM 91, a 25-mer phosphorothioate oligonucleotide complementary to the gag site of HIV, in the monkey produces transient decreases in peripheral total WBC and neutrophil counts, hemoconcentration, and a brief increase followed by a prolonged decrease in arterial blood pressure. These changes are preceded by and are likely mediated by activation of C5 complement. These effects are dose and infusion rate dependent and can be avoided by administering GEM 91 by slow intravenous infusion. Similar hemodynamic effects are produced with rapid intravenous infusion of other phosphorothioate oligonucleotides varying in length from 20- to 33-mer, and are, therefore, not sequence specific but a property of this chemical structure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7849490     DOI: 10.1089/ard.1994.4.201

Source DB:  PubMed          Journal:  Antisense Res Dev        ISSN: 1050-5261


  32 in total

Review 1.  Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.

Authors:  R L Juliano; S Alahari; H Yoo; R Kole; M Cho
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

Review 2.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

Review 3.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 4.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

5.  New modalities in oncology: antisense oligonucleotides.

Authors:  C Casey Cunningham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-04

6.  Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes.

Authors:  P L Nicklin; D Bayley; J Giddings; S J Craig; L L Cummins; J G Hastewell; J A Phillips
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

7.  Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments.

Authors:  E R Kandimalla; A Manning; Q Zhao; D R Shaw; R A Byrn; V Sasisekharan; S Agrawal
Journal:  Nucleic Acids Res       Date:  1997-01-15       Impact factor: 16.971

Review 8.  Therapeutic targeting of microRNAs: current status and future challenges.

Authors:  Zhonghan Li; Tariq M Rana
Journal:  Nat Rev Drug Discov       Date:  2014-07-11       Impact factor: 84.694

9.  Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.

Authors:  G Hartmann; A Krug; K Waller-Fontaine; S Endres
Journal:  Mol Med       Date:  1996-07       Impact factor: 6.354

Review 10.  Small molecules targeting microRNA for cancer therapy: Promises and obstacles.

Authors:  Di Wen; Michael Danquah; Amit Kumar Chaudhary; Ram I Mahato
Journal:  J Control Release       Date:  2015-08-06       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.